No Detail Found!

Association of Clinical Parameters and Interferon Alpha/beta Receptor Subunit 2 in HCV Patients Resistant to Interferon Therapy.

Author(s)
Gulshan Ara Trali Department of Biochemistry, HITEC-Institute of Medical Sciences, Taxila Cantt, Pakistan
Ambreen Javed Department of Biochemistry, HITEC-Institute of Medical Sciences, Taxila Cantt, Pakistan
Alia Sadiq Department of Biochemistry, HITEC-Institute of Medical Sciences, Taxila Cantt, Pakistan
Abdul Khaliq Naveed CMH Lahore Medical College, Lahore, Pakistan
Abstract
Background: Interferon therapy is an expensive treatment for hepatitis C virus (HCV) which may results in undesirable side effects. About 50% of chronic HCV patients do not respond to interferon (IFN) therapy for unknown reasons. It is important to determine the association of clinical parameters with IFNAR-2 in HCV patients, resistant to IFN therapy. Methods: HCV genotype 3 patients were included in study (n=20, between 30-60 age group) and categorized into two groups, the experimental group including patients responding to interferon treatment and the control group consisting of interferon resistant patients. Blood samples and Liver biopsy specimens were collected from all HCV patients. Clinical parameters included in the study were (i) pre-biopsy tests (platelet count, bleeding time, prothrombin time) (ii) HCV viral genotype 3 (iii) HCV-RNA and (iv) liver functions (ALT, ALP, and bilirubin). Molecular investigations were carried out by using PCR and gel electrophoresis to identify IFNAR-2 in all HCV genotype 3 patients. Results: Experimental results from clinical testing of non-responder (resistant) group, showed significantly increased ALT level (64.13±17.48 U/L) as compared to responder group (46±6.3 U/L). Hemoglobin (Hb) level was also found significantly increased in non-responder group (12.9±1.8 g/dL) in comparison with responder group (10.3±0.48 g/dL). Further molecular testing revealed that all interferon resistant patients showed the presence of IFNAR-2. Conclusion: Experimental observations revealed that non-responder HCV genotype 3 patients showed elevated ALT and Hb levels and presence of IFNAR-2 protein. Therefore, experimental results of this study signify the importance of monitoring clinical parameters in parallel with IFN therapy in non-responder HCV patients.
Publication Details
Page(s) 33-36
DOI DOI not available
Published Journal: Pakistan Journal of Physiology, Volume: 14, Issue: 1, Year: 2018

Request the full text from PASTIC

References
RaghuramanS,ParkH,OsburnWO,WinkelsteinE,EdlinBR,RehermannB, 2012.Spontaneous clearance of chronic Hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion,J Infect Dis 205 763 -71
WilderJ,PatelK., 2014.A review of the natural history of chronic hepatitis C infection,North Am J Med Sci 7 1 -7
ZhuRX,SetoWK,LaiCL,YuenMF, 2016.Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region,Gut Liver 10 332 -9
MichaelCK, 2014.Hepatocellular carcinoma: epidemiology and risk factors,J Hepatocell Carcinoma 1 115 -25
WestbrookRH,DusheikoG, 2014.Natural history of hepatitis C,J Hepatol 61 S58 -68
RazzaqZ,MalikA, 2014.Viral load is associated with abnormal serum levels of micronutrients and glutathione and glutathionedependent enzymes in genotype 3 HCV patients,BBA Clin 2 72 -8
Sosa-JuradoF,Hernández-GalindoVL,Meléndez-MenaD,Mendoza-TorresMA,Martínez-ArronizFJ,Vallejo-RuizV, 2014.Detection of hepatitis C virus RNA in saliva of patients with active infection not associated with periodontal or liver disease severity,BMC Infect Dis 14 72 -
MohamedAA,ElbedewyTA,El-SerafyM,El-ToukhyN,AhmedW,Ali El Din Z. Hepatitis C virus:, 2015.A global view,World J Hepatol 7 2676 -80
RingehanM,McKeatingJA,ProtzerU, 2017.Viral hepatitis and liver cancer,Philos Trans R Soc Lond B Biol Sci 20160274 -
de WeerdNA,NguyenT., 2012.The interferons and their receptorsdistribution and regulation,Immunol Cell Biol 90 483 -91
NagaokiY,ImamuraM,AikataH,DaijoK1,TeraokaY1,HondaF, 2017.The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy,PLoS One 12 e0182710d -
JiF,ZhangS,DengH, 2013.Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: Further evidence in decompensation cirrhosis,J Hepatol 58 1262 -4
CavalcanteLN,LyraAC, 2015.Predictive factors associated with hepatitis C antiviral therapy response,World J Hepatol 7 1617 -31
PolS,CorougeM,Vallet-PichardA, .Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life,Hepat Med 15. -
2018.Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response,Liver Int 38 59 -67
GastroenterolRep, 2016., 4 24 -9
KanwalF,KramerJR,IlyasJ,DuanZ,El-SeragHB, 2014.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US. Veterans with HCV,Hepatology 60 98 -105
KanwalS,MahmoodT, 2014.Hepatitis C virus resistance to interferon therapy: an alarming situation,Cent Eur J Biol 9 1155 -67
BrjalinV.,HussainS,QureshiS,MalikSA,KazmiAR,NaeemM., 2012.Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus-infected patients,BMC Gastroenterol 12 117 -
DustinLB,CashmanSB,LaidlawSM, 2014.Immune control and failure in HCV infection-tipping the balance,J Leukoc Biol 96 535 -48
Interferon alpha (IFNα, 2016.-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A,Cell Mol Immunol 13 94 -102
FrodshamAJ,ZhangL,DumpisU,TaibNA,BestS,DurhamA, 2006.Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence,Proc Natl Acad Sci USA 103 9148 -53
2013.peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection,J Interferon Cytokine Res 33 405 -14
ChandraPK,GunduzF,HazariS,KurtR,PanigrahiR,PoatB, 2014.Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis,PLoS One 9 e108616 -
TaniguchiH,IwasakiY,TakahashiA,ShimomuraH,MoriyaA,YuPC, 2007.Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C,Intervirology 50 32 -9
FriborgJ,LinB,ChenC, 2013.Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines,Virology 444 384 -93
0

Citations

0

Downloads

112

Views